Press Release

Date: June 26, 2026 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock Code : INDOCO Dear Sir/Madam, Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Completion of Inspection at Indoco Remedies Limited Goa Unit-I Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Malta Medicines Authority had inspected Company’s manufacturing facility for solid oral dosage form (Plant I) located at Goa (“Facility”), from November 19 to November 24, 2025. The Facility has received EU GMP certification from the Malta Medicines Authority confirming that the Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive. Please find enclosed herewith press release in this regard. Kindly take the above information on record. Thanking you, Yours faithfully, For Indoco Remedies Limited Ramanathan Hariharan Company Secretary & Head Legal PRESS RELEASE Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit Mumbai, June 26, 2026: Indoco Remedies Ltd. has announced today that the Malta Medicines Authority had inspected the Company’s manufacturing facility for solid oral dosage form (Plant I) located at Goa, from November 19 – November 24, 2025. The facility has received EU GMP certification from the Malta Medicines Authority confirming that it complies with the Good Manufacturing Practice requirements as referred in the EC Directive. Commenting on this development, Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd. said, “Compliance is a core value that drives our quality systems. This approval reinforces our commitment to delivering highest quality healthcare to our customers worldwide.” About Indoco Remedies Limited: Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is US$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization. The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Otorex, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69 etc. On the international front, Indoco has tie-ups with large generic companies across the globe. For more details on Indoco, you may visit www.indoco.com For Media enquiries please contact: Tel. | +91 22 62871000 E-mail: corpcom@indoco.com